Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
3.06M | 1.08M | 0.00 | 0.00 | 0.00 | Gross Profit |
1.60M | 488.00K | -2.58M | -1.04M | -894.00K | EBIT |
-108.58M | -111.17M | -123.84M | -96.91M | -36.69M | EBITDA |
-108.58M | -91.80M | -129.86M | -95.87M | -35.80M | Net Income Common Stockholders |
-101.01M | -95.96M | -141.04M | -88.95M | -36.61M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
209.60M | 257.74M | 351.31M | 471.30M | 36.91M | Total Assets |
247.87M | 298.25M | 391.49M | 503.23M | 40.59M | Total Debt |
12.95M | 15.30M | 17.45M | 8.08M | 1.75M | Net Debt |
-36.29M | -118.56M | -66.87M | -27.71M | -35.16M | Total Liabilities |
32.45M | 26.63M | 32.78M | 26.19M | 4.50M | Stockholders Equity |
215.42M | 271.62M | 358.71M | 477.03M | 36.09M |
Cash Flow | Free Cash Flow | |||
-92.38M | -99.31M | -101.30M | -72.58M | -33.03M | Operating Cash Flow |
-87.80M | -94.04M | -90.56M | -66.81M | -32.57M | Investing Cash Flow |
-32.67M | 143.43M | 137.19M | -450.94M | -461.00K | Financing Cash Flow |
35.88M | 149.00K | 1.91M | 516.63M | 37.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $291.78M | ― | -41.31% | ― | ― | -7.93% | |
57 Neutral | $225.75M | ― | 322.49% | ― | -30.66% | 36.48% | |
56 Neutral | $352.32M | ― | -40.23% | ― | 167.94% | -3.66% | |
54 Neutral | $115.38M | ― | -24.73% | ― | -1.02% | -8.59% | |
53 Neutral | $5.19B | 3.33 | -45.04% | 2.83% | 17.58% | -0.66% | |
47 Neutral | $252.46M | ― | -30.47% | ― | ― | -22.66% | |
41 Neutral | $97.51M | ― | -30.93% | ― | ― | -1.20% |
On May 16, 2025, Quantum-Si held its Annual Meeting where shareholders voted on three key proposals. The meeting saw the reelection of board members, the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025, and the approval of executive compensation, reflecting strong shareholder support for the company’s governance and financial strategies.
The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.
On April 10, 2025, Quantum-Si Incorporated updated its corporate presentation, highlighting its strategic positioning in the expanding proteomics market. The company’s Proteus platform, expected to launch in the second half of 2026, aims to revolutionize proteomics research by offering single-molecule, top-down, and bottom-up methods. Quantum-Si’s technology is designed to address the complexities of proteomics analysis and is anticipated to transform the field from a complementary to a primary technology in research. The company’s advancements are expected to accelerate commercial adoption, evidenced by a 183% year-over-year growth.